SOURCE: Helix BioPharma Corp.

Helix BioPharma Corp.

January 10, 2014 10:36 ET

Director of Helix BioPharma Corp. Acquires a Further 1,000,000 Common Shares

AURORA, ON--(Marketwired - Jan 10, 2014) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company dedicated to developing drugs for prevention and treatment of cancer, today announced that it has been advised by Dr. Marek Orlowski, a member of the board of directors of Helix and Chairman of the Supervisory Board of Helix Polska, that he has purchased 1,000,000 previously issued and outstanding shares of Helix for a total purchase price of approximately CAD$1.72 million since December 30, 2013.

Dr. Orlowski now holds an aggregate of 1,710,000 shares of Helix. 

About Helix BioPharma Corp. 

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Contact Information